Interventions for Tuberculosis Control and Elimination 2002

1021. Helmy B.
220-5.
Side effects of cycloserine. Scand J Respir Dis 1970; 71 (Suppl):
1022. Pasargiklian M, Biondi L. Neurologic and behavioural reactions of tuberculous
patients treated with cycloserine. Scand J Respir Dis 1970; 71 (Suppl): 201-8.
1023. Schultka H. D-Cycloserin bei Tuberkulösen mit gleichzeitig bestehendem psychiatrisch-neurologischem
Krankheitsbild. Tuberkulosearzt 1961; 15: 251-4.
1024. Vítek V, Rysánek K. Interaction of D-cycloserine with the action of some
monoamine oxidase inhibitors. Biochem Pharmacol 1965; 14: 1417-23.
1025. Akula SK, Aruna AS, Johnson JE, Anderson DS. Cycloserine-induced Stevens-
Johnson syndrome in an AIDS patient with multidrug-resistant tuberculosis.
J Tuberc Lung Dis 1997; 1: 187-90.
Int
1026. Glass F, Mallach HJ, Simsch A. Beobachtungen und Untersuchungen über die
gemeinsame Wirkung von Alkohol und D-Cycloserin. Drug Res 1965; 15: 684-8.
1027. Bernheim F. The effect of salicylate on the oxygen uptake of the tubercle bacillus.
Science 1940; 92: 204.
1028. Lehmann J. Para-aminosalicylic acid in the treatment of tuberculosis. Lancet
1946; 1: 15-6.
1029. Lehmann J. Twenty years afterward. Historical notes on the discovery of the
antituberculosis effect of para-aminosalicylic acid (PAS) and the first clinical
trials. (Editorial). Am Rev Respir Dis 1964; 90: 953-6.
1030. Dubovsky H. The history of para-aminosalicylic acid (pas), the first tuberculosis
anti-microbial agent, and streptomycin (sm): a comparative study.
Museum Bulletin 1988; 14: 7-11.
Adler
1031. Dubovsky H. Correspondence with a pioneer, Jürgen Lehmann (1898-1989),
producer of the first effective antituberculosis specific.
48-50.
S Afr Med J 1991; 79:
1032. Peloquin CA, Berning SE, Huitt GA, Childs JM, Singleton MD, James GT.
Once-daily and twice-daily dosing of p-aminosalicylic acid granules.
Respir Crit Care Med 1999; 159: 932-4.
Am J
1033. Fodor T, Pataki G, Schrettner M. PAS infusion in treatment of multidrug-resistant
tuberculosis. (Correspondence). Int J Tuberc Lung Dis 2000; 4: 187-8.
1034. Anonymous. PAS. (Leading article). Tubercle 1973; 54: 165-7.
1035. British Medical Research Council. Co-operative controlled trial of a standard
regimen of streptomycin, PAS and isoniazid and three alternative regimens of
chemotherapy in Britain. Tubercle 1973; 54: 99-129.
1036. Huang KL, Beutler SM, Wang C. Hypothyroidism in a patient receiving treatment
for multidrug-resistant tuberculosis. Clin Infect Dis 1998; 27: 910.
1037. Soumakis SA, Berg D, Harris HW. Hypothyroidism in a patient receiving treatment
for multidrug-resistant tuberculosis. Clin Infect Dis 1998; 27: 910-1.
238